🧵Cardiogenic shock after acute MI (AMI-CS) has high in-hospital mortality. But what about long-term outcomes? This matters as much to patients. Our new JACC Journals paper (co-led by Lee_Sterling) looked at long-term outcomes in AMI-CS. OPEN ACCESS: sciencedirect.com/science/articl…

This work was led by Lee_Sterling, with support from Benjamin Hibbert and Peter Tanuseputro. A special thanks to our team of co-investigators: Danial Qureshi Sean van Diepen @susannaprice Eddy Fan @DiSantoPietro Richard Jung Simon Parlow Babar Basir rebecca mathew Holger Thiele

Incredible thanks to Shannon Fernando Benjamin Hibbert Peter Tanuseputro rebecca mathew and everyone else on our co-investigator team for all of their support, and expertise to see this project through from start to finish!

Mechanisms of benefits of #SGLT2i in #HFpEF and the Multifaceted Benefits of SGLT2i 📌Regulation of blood sugar, blood pressure, and kidney disease progression. 📌Induction of nutrient-deprivation responses leading to increased ketosis and erythropoietin. 📌Improvement in

The sodium-glucose cotransporter2 inhibitors are robust, disease-modifying therapies in heart failure with preserved ejection fraction. Discover the mechanisms of benefits of #SGLT2 in #HF with preserved EF in #EHJ doi.org/10.1093/eurhea… #cardiotwitter European Society of Cardiology Journals European Society of Cardiology

✔️ SGLT2 inhibitors have been shown to ↘️ myofilament stiffness & extracellular matrix remodeling/fibrosis in the heart, improving diastolic function. Read more 🔑 points from a state-of-the-art review on SGLT2 inhibitors in patients w/ #HFpEF: bit.ly/46ieJMf #cvPrev

STRATUS Trial published JAMA 🩸Cluster trial 25 ICUs >27,000 patients 🩸Switch to “small-volume” tubes that⬇️blood drawn for lab tests may⬇️RBC transfusion↔️effect on testing 🩸Available, cost-neutral, compatible with analyzers – will you switch? jamanetwork.com/journals/jama/…

Congrats to Ottawa IM’s Jun Yi for placing on the podium 2 years in a row!

Mechanisms of benefits of sodium-glucose cotransporter 2 inhibitors in heart failure with preserved ejection fraction European Society of Cardiology Journals European Society of Cardiology academic.oup.com/eurheartj/adva…

Simon Parlow presenting the design and rationale of the #DOREMI2 study evaluating inotropes vs. placebo in cardiogenic shock #VASC23

Congratulations to Avinash Pandey MD for winning the SANSAR Foundation #sansarburgundy young investigator award for his research assessing the uptake of #GDMT in #ASCVD in the #southasian population in Canada.

Presented at #ACC24: Hospitalized patients with acute myocardial infarction & preserved EF were assigned to receive open-label long-term beta-blocker therapy or not. Beta-blockers did not lead to a lower risk of death or MI. Full REDUCE-AMI trial results: nej.md/4akVhRx

After 10 years to complete it, the DanGer-SHOCK trial showed that the routine use of a microaxial flow pump with standard care in the treatment of patients with STEMI-related cardiogenic shock led to a lower risk of death from any cause at 180 days than standard care alone. The

***BREAKING NEWS*** WNBA in The Six is official. Larry Tannenbaum's Kilmer Sports Inc has finalized the deal. What a time for women's sports in Canada! cbc.ca/sports/basketb…

They are a PROBLEM. 😈 #Paris2024 x #Basketball

Mortality in cardiogenic shock may exceed 50%. In this meta-analysis of 160 studies, Jung et al. identified several modifiable and non-modifiable patient-, presentation-, and procedural-related prognostic factors associated with early mortality. 🔗 eviden.cc/4fa9kLH